Journal Watch · European Heart Journal · 2026

Aspirin vs clopidogrel in chronic coronary syndromes: a meta-analysis of ethnic differences.

However, a high level of confidence in these findings is currently limited to East Asian populations, and additional evidence is needed to clarify their applicability to non-East Asian patients.<h4>Study registration</h4>PROSPERO (CRD420251145176).

Laudani C, Occhipinti G, Costa F et al.European Heart Journal3 min readPharma relevance 65/100

DOI: 10.1093/eurheartj/ehag351PMID: 42154959Study type: randomised / controlled clinical trial

TL;DR

However, a high level of confidence in these findings is currently limited to East Asian populations, and additional evidence is needed to clarify their applicability to non-East Asian patients.<h4>Study registration</h4>PROSPERO (CRD420251145176).

Key findings

  • The results were consistent in the East Asian population, whereas a significant interaction by ethnicity was observed for MACE (East Asians: IRR 0.76, 95% CI 0.59-0.98; non-East Asians: IRR 1.00, 95% CI 0.74-1.36; Pint = 0.010) and mortality (Pint = 0.014), with no significant benefits observed in non-East Asian patients.
  • The analyses were statistically powered for most outcomes in East Asian populations but for none in non-East Asian populations.<h4>Conclusions</h4>In patients with CCS, the overall body of evidence suggests improved outcomes with clopidogrel compared with aspirin, without an apparent effect on mortality.
  • However, a high level of confidence in these findings is currently limited to East Asian populations, and additional evidence is needed to clarify their applicability to non-East Asian patients.<h4>Study registration</h4>PROSPERO (CRD420251145176).

Numbers at a glance (from the abstract)

75.1%95%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Trial sequential analysis was used to assess the statistical power of the results.<h4>Results</h4>Seven RCTs were included, encompassing 30 165 patients, of whom 75.1% were East Asians. Median follow-up was 36.0 months. Overall, clopidogrel was associated with significant reductions in MACE (incidence rate ratio [IRR] 0.83, 95% confidence interval [CI] 0.69-0.99) and net adverse clinical events (IRR 0.83, 95% CI 0.69-0.99), compared with aspirin. There were no differences between groups in major bleeding, myocardial infarction, or mortality.

Full abstract (original)

Background: <h4>Background and aims</h4>Emerging data suggest that, in patients with chronic coronary syndromes (CCS), clopidogrel provides superior antithrombotic protection compared with aspirin for secondary prevention, without an associated increase in bleeding risk. The consistency of the observed benefits across ethnicities remains uncertain.<h4>Methods</h4>Randomized controlled trials (RCTs) comparing aspirin vs clopidogrel for secondary prevention in patients with CCS were screened. The primary endpoint was trial-defined major adverse cardiovascular events (MACE). Prespecified subgroup interaction by ethnicity (East Asian vs non-East Asian) was performed.

What they did: Trial sequential analysis was used to assess the statistical power of the results.<h4>Results</h4>Seven RCTs were included, encompassing 30 165 patients, of whom 75.1% were East Asians. Median follow-up was 36.0 months. Overall, clopidogrel was associated with significant reductions in MACE (incidence rate ratio [IRR] 0.83, 95% confidence interval [CI] 0.69-0.99) and net adverse clinical events (IRR 0.83, 95% CI 0.69-0.99), compared with aspirin. There were no differences between groups in major bleeding, myocardial infarction, or mortality.

Results & conclusions: The results were consistent in the East Asian population, whereas a significant interaction by ethnicity was observed for MACE (East Asians: IRR 0.76, 95% CI 0.59-0.98; non-East Asians: IRR 1.00, 95% CI 0.74-1.36; Pint = 0.010) and mortality (Pint = 0.014), with no significant benefits observed in non-East Asian patients. The analyses were statistically powered for most outcomes in East Asian populations but for none in non-East Asian populations.<h4>Conclusions</h4>In patients with CCS, the overall body of evidence suggests improved outcomes with clopidogrel compared with aspirin, without an apparent effect on mortality. However, a high level of confidence in these findings is currently limited to East Asian populations, and additional evidence is needed to clarify their applicability to non-East Asian patients.<h4>Study registration</h4>PROSPERO (CRD420251145176).

Abstract © the authors / European Heart Journal (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1093/eurheartj/ehag351 · PubMed 42154959.

Why it matters for pharma & biotech

  • Relevant to Pharmacology & Drug Discovery teams tracking European Heart Journal for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this European Heart Journal study find?

However, a high level of confidence in these findings is currently limited to East Asian populations, and additional evidence is needed to clarify their applicability to non-East Asian patients.<h4>Study registration</h4>PROSPERO (CRD420251145176).

What type of study is this?

It is a randomised / controlled clinical trial, published in European Heart Journal in 2026. Trial sequential analysis was used to assess the statistical power of the results.<h4>Results</h4>Seven RCTs were included, encompassing 30 165 patients, of whom 75.1% were East Asians.

Where can I read the original paper?

The original is at the publisher via DOI 10.1093/eurheartj/ehag351. PubMed ID: 42154959. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Laudani C, Occhipinti G, Costa F et al.. Aspirin vs clopidogrel in chronic coronary syndromes: a meta-analysis of ethnic differences.. European Heart Journal (2026). DOI: 10.1093/eurheartj/ehag351.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/aspirin-vs-clopidogrel-in-chronic-coronary-syndromes-a-meta-analysis-of-hag351/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides